Historie von Umsatz, Gewinn und Cashflow aus den offiziellen Geschäftsberichten.
Zimmer Biomet Holdings, Inc., together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T.
Interaktive Charts und vollständige Abschlüsse ansehen → Bewertungsmodell (DCF) →
| Gewinn- und Verlustrechnung | TTM → 2026-06-30 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 | 2016-12-31 | 2015-12-31 | 2014-12-31 | 2013-12-31 | 2012-12-31 | 2011-12-31 | 2010-12-31 | 2009-12-31 | 2008-12-31 | 2007-12-31 | 2006-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gesamtumsatz | $8.5B | $8.2B | $7.7B | $7.4B | $6.9B | $6.8B | $6.1B | $8.0B | $7.9B | $7.8B | $7.7B | $6.0B | $4.7B | $4.6B | $4.5B | $4.5B | $4.2B | $4.1B | $4.1B | $3.9B | $3.5B |
| Bruttoergebnis | $5.9B | $5.1B | $5.5B | $5.3B | $4.9B | $4.9B | $4.3B | $5.7B | $5.7B | $5.7B | $5.3B | $4.2B | $3.4B | $3.3B | $3.3B | $3.3B | $3.2B | $3.1B | $3.1B | $3.0B | $2.7B |
| Bruttomarge % | 69.9% | 61.6% | 71.5% | 71.8% | 70.9% | 71.3% | 70.2% | 71.8% | 71.4% | 72.7% | 68.9% | 70.0% | 73.4% | 72.2% | 74.8% | 74.8% | 76.0% | 75.8% | 75.8% | 77.5% | 77.7% |
| Betriebsergebnis (EBIT) | $1.4B | $1.4B | $1.3B | $1.3B | $696M | $860M | $83M | $1.1B | $34M | $799M | $821M | $467M | $1.0B | $1.0B | $1.0B | $1.0B | $917M | $1.0B | $1.1B | $1.1B | $1.2B |
| Operative Marge % | 16.3% | 16.6% | 16.7% | 17.3% | 10.0% | 12.6% | 1.4% | 14.2% | 0.4% | 10.2% | 10.7% | 7.8% | 22.2% | 22.4% | 23.4% | 23.0% | 21.7% | 24.9% | 26.5% | 28.9% | 33.3% |
| Jahresüberschuss | $807M | $705M | $904M | $1.0B | $231M | $402M | ($139M) | $1.1B | ($379M) | $1.8B | $306M | $147M | $720M | $761M | $755M | $761M | $597M | $717M | $849M | $773M | $834M |
| Nettomarge % | 9.5% | 8.6% | 11.8% | 13.9% | 3.3% | 5.9% | -2.3% | 14.2% | -4.8% | 23.2% | 4.0% | 2.5% | 15.4% | 16.5% | 16.9% | 17.1% | 14.1% | 17.5% | 20.6% | 19.8% | 23.9% |
| EBITDA | — | $2.2B | $2.3B | $2.2B | $1.5B | $1.6B | $1.0B | $2.1B | $1.1B | $1.9B | $1.8B | $1.2B | $1.4B | $1.4B | $1.4B | $1.4B | $1.3B | $1.5B | $1.4B | $1.4B | $1.4B |
| Ergebnis je Aktie (EPS) | $4.11 | $3.55 | $4.43 | $4.88 | $1.10 | $1.91 | $-0.67 | $5.47 | $-1.86 | $8.90 | $1.51 | $0.77 | $4.20 | $4.43 | $4.29 | $4.03 | $2.97 | $3.32 | $3.72 | $3.26 | $3.40 |
| Ausstehende Aktien (Mio.) | — | 199M | 204M | 210M | 210M | 210M | 207M | 207M | 204M | 204M | 202M | 190M | 172M | 172M | 176M | 189M | 201M | 216M | 228M | 238M | 245M |
Quelle: veröffentlichte Unternehmensberichte (SEC). Bitte prüfen Sie die Zahlen vor Verwendung auf SEC EDGAR.
Bilanzen, Cashflow-Rechnungen, Quartalsdaten und alle Kennzahlen finden Sie im interaktiven Viewer für ZBH. /companies/us/ZBH
Die Informationen auf dieser Website dienen ausschließlich Bildungs- und Informationszwecken und stellen keine Anlageberatung dar. Es werden keine Kursziele und keine Anlageurteile veröffentlicht.
About TickerBase · Data methodology & sources · Privacy · Terms